<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Mon, 29 Jun 2026 20:37:31 -0400--><rss version="2.0">
    <channel>
        <title>Capricor Therapeutics, Inc. (CAPR) Press Releases</title>
        <link>https://www.capricor.com/investors/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/capricor/files/theme/images/logo-sm.png</url>
                <title>Capricor Therapeutics, Inc. Logo</title>
                <link>/investors</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/348/capricor-therapeutics-announces-fda-advisory-committee</link>
                <pubDate>Fri, 26 Jun 26 10:02:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/348/capricor-therapeutics-announces-fda-advisory-committee</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and</link>
                <pubDate>Fri, 26 Jun 26 09:05:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/347/capricor-to-present-positive-five-year-hope-2-ole-data-and</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics to Present at Upcoming Investor Conferences]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/346/capricor-therapeutics-to-present-at-upcoming-investor</link>
                <pubDate>Mon, 08 Jun 26 09:25:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/346/capricor-therapeutics-to-present-at-upcoming-investor</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Expands Commercial Leadership Team]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/345/capricor-therapeutics-expands-commercial-leadership-team</link>
                <pubDate>Thu, 28 May 26 21:55:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/345/capricor-therapeutics-expands-commercial-leadership-team</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/344/capricor-therapeutics-reports-first-quarter-2026-financial</link>
                <pubDate>Tue, 12 May 26 16:05:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/344/capricor-therapeutics-reports-first-quarter-2026-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/343/capricor-therapeutics-takes-legal-action-to-protect-patient</link>
                <pubDate>Thu, 07 May 26 17:00:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/343/capricor-therapeutics-takes-legal-action-to-protect-patient</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/342/capricor-therapeutics-to-report-first-quarter-2026</link>
                <pubDate>Mon, 04 May 26 16:05:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/342/capricor-therapeutics-to-report-first-quarter-2026</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/341/capricor-therapeutics-announces-late-breaking-presentation</link>
                <pubDate>Wed, 22 Apr 26 09:00:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/341/capricor-therapeutics-announces-late-breaking-presentation</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year</link>
                <pubDate>Thu, 12 Mar 26 16:01:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.capricor.com/investors/news-events/press-releases/detail/339/capricor-therapeutics-announces-late-breaking-hope-3-data</link>
                <pubDate>Thu, 12 Mar 26 09:00:00 -0400</pubDate>
                <guid>https://www.capricor.com/investors/news-events/press-releases/detail/339/capricor-therapeutics-announces-late-breaking-hope-3-data</guid>
                                                                            </item>
            </channel>
</rss>